FULC Fulcrum Therapeutics

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced upcoming presentations at the 5th Global Congress on Sickle Cell Disease and the 2025 European Hematology Association Congress.

The Company’s presentations are listed below. Following congress publication, copies of the presentations will be available in the "Publications & Presentations" section of the Company's website at .

5th Global Congress on Sickle Cell Disease, Abuja, Nigeria, June 3-6, 2025:

  • Poster Presentation: Preclinical and Early Clinical Results of Pociredir, a Novel, Oral, Potent Fetal Hemoglobin Inducer for the Treatment of Sickle Cell Disease (SCD) (Presentation ID: 103, Tuesday, June 4)
  • Poster Presentation: A Phase 1b, Open-Label, Multiple-Dose Study Evaluating Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Pociredir in Patients with Sickle Cell Disease (SCD): Trial Design (Presentation ID: 101, Tuesday, June 4)



2025 European Hematology Association Congress, Milan, Italy, June 12-15, 2025

  • Poster Presentation: Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of the Novel Oral Fetal Hemoglobin (HBF) Inducer Pociredir in Healthy Adults in a Phase 1 study (PF1170 – Friday, June 13)
  • Poster Presentation: Pociredir, a Potent and Selective EED Inhibitor for the Treatment of Sickle Cell Disease, Induces Target Engagement and Gene Expression Changes that are Specific and Reversible in Wild-Type Mice (PS2175 – Saturday, June 14)



About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

About Pociredir

Pociredir is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED) that was discovered using Fulcrum’s proprietary discovery technology. Inhibition of EED leads to potent downregulation of key fetal globin repressors, including BCL11A, thereby causing an increase in fetal hemoglobin (HbF). Pociredir is being developed for the treatment of SCD. Initial data in SCD demonstrated proof-of-concept and achieved absolute levels of HbF increases associated with potential overall patient benefit. In clinical trials conducted prior to the clinical hold, which was lifted by the FDA in August 2023, pociredir was generally well-tolerated in people with SCD with up to three months of exposure, with no serious treatment-related adverse events reported. Pociredir has been granted FDA Fast Track designation and Orphan Drug Designation for the treatment of SCD. To learn more about these trials please visit .

About Sickle Cell Disease

Sickle cell disease (SCD) is a genetic disorder of the red blood cells caused by a mutation in the HBB gene. This gene encodes a protein that is a key component of hemoglobin, a protein complex whose function is to transport oxygen in the body. The result of the mutation is less efficient oxygen transport and the formation of red blood cells that have a sickle shape. These sickle shaped cells are much less flexible than healthy cells and can block blood vessels or rupture cells. People with SCD typically suffer from serious clinical consequences, which may include anemia, pain, infections, stroke, heart disease, pulmonary hypertension, kidney failure, liver disease, and reduced life expectancy.

Contact:

Kevin Gardner

LifeSci Advisors, LLC



617-283-2856



EN
29/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fulcrum Therapeutics

 PRESS RELEASE

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

Fulcrum Therapeutics to Present at Upcoming Medical Meetings CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced upcoming presentations at the 5th Global Congress on Sickle Cell Disease and the 2025 European Hematology Association Congress. The Company’s presentations are listed below. Following congress publication, copies of the presentations will be available ...

 PRESS RELEASE

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs G...

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, FL on Wednesday, June 11, 2025 at 8:00 am ET. The webcast of the fireside chat will be acce...

 PRESS RELEASE

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Ru...

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as ...

 PRESS RELEASE

Fulcrum Therapeutics to Participate in Upcoming May Conferences

Fulcrum Therapeutics to Participate in Upcoming May Conferences CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences: H.C. Wainwright BioConnect Investor Conference at NASDAQMay 20, 2025New York, New York RBC Capital Markets Global Healthcare ConferenceMay 21, 2025Fireside Chat at 3:35 pm ET, Participa...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch